Small Caps round-up: eXpansys, Oxford Biomedica, Dawson International

eXpansys, the online electronics retailer has delivered a 33 per cent increase in turnover in the 12 months to the end of April. Total revenues for the year were 108.5m pounds, up 24pc on a like-for-like basis. Profits before tax were 4.3m pounds, a rise of 27pc on the prior year. The market had clearly been expecting better, the stock was down 3.8pc at 10:34.

By MoneyWeek

published 8 August 2012

in Features

Oxford BioMedica, a gene-based pharma company, says an early study of a treatment for macular degeneration has shown positive results. The "Phase 1" study for RetinoStat, on nine patients, has delivered retinal transduction with no serious adverse events. The stock was up 1.6% by 10:41.

Knitwear firm Dawson International has had its shares suspended on AIM after concerns were raised by the trustees of its defined benefits pension plans. The trustees have served a formal notice which may result in the firm going into administration. Today's press release emphasises that there is "no intention to appoint administrators for the US knitwear business, Dawson Forte, which is well funded and continues to trade normally."